Kornimate/medical-research-clean huggingface dataset:
effects of dry needling on function, muscle tone and quality of life in parkinson's disease

Conditions: Parkinson Disease

Summary: hypothesis: dry needling in lower limbs produces a change in function (assessed by the 6 minute walk test, timed up and go, 10 meter walk test and unified scale for parkinson's disease) and muscle tone (assessed by tonometry and the modified of modified ashworth scale(mmas)) in patients with parkinson's disease. the main objective of this study is to analyze the effect of dry needling on function and muscle tone in subjects with parkinson disease. the secondary objective is to analyze the longterm effects of dry needling on function and muscle tone in subjects with parkinson disease.

methods: it is a double-blinded randomized clinical trial where subjects are patients from zaragoza and have been diagnosed with parkinson´disease by a neurologist. inclusion criteria: * patients diagnosed with parkinson by a neurologist. * age: 50 - 90 years. * presence of hypertonia according to: mmas score \> 1 during movement of ankle dorsiflexion or knee flexion and extension. exclusion criteria: * degenerative diseases that may affect the results. * presence of fixed contractures. * fear of needles. * no tolerance to pain caused by dry needling * no commitment to continuity. * attrition criteria attrition criteria: * adverse effects relate to the dnhs technique. * subject uncooperative that prevents proper protocol execution performance -voluntary decision of the patient. intervention: there will be an intervention group (dry needling into the muscles of the lower limbs that present tone dysfunction according to an expert clinician) and a control group (sham dry needling). the intervention will be a unique session. dry needling technique will be performed by locating the taut band and the myofascial trigger point by an expert clinician. after that, a thin needle (0,32x40mm) is introduced directly into a myofascial trigger point with the aims to generate a "local twitch response" that are involuntary contractions of the muscle fibers. this puncture may reproduce patient's symptoms, and causes muscle relaxation to achieve at the same time the relief of muscle tension and pain and also to recover the metabolism of the muscle. assessment: outcome measures will include tone muscle measured by tonometry and the mmas and functional clinical scales including: 6 minute walk test, timed up and go, 10 meter walk test and unified parkinson's disease rating scale.

Eligibility criteria:
inclusion criteria: * patients diagnosed with parkinson by a neurologist * age: 50 - 90 years * presence of hypertonia according to: mmas score \> 1 during movement of ankle dorsiflexion or knee flexion and extension exclusion criteria: * degenerative diseases that may affect the results. * presence of fixed contractures. * fear of needles * no tolerance to pain caused by dry needling * no commitment to continuity

Keywords: dry needling parkinson disease myofascial trigger point
tamoxifen compared with clomiphene citrate for women who had thin endometrium women under clomiphene in a previous cycle

Conditions: Infertility

Summary: about 10-15% of all couples attempting to conceive will not become pregnant within one year. among those, the majority will have ovulatory dysfunction, mild male infertility or unexplained infertility. the traditional first line therapy for those couples is ovulation induction or superovulation using clomiphene citrate. probably due to anti-estrogenic effects of this agent will, some patients will have a thin endometrium as measured by sonography at the time of ovulation. this phenomenon may be associated with a lower chance to conceive. tamoxifen is a similar molecule that has been used to clomiphene citrate that has been shown to be equally effective to clomiphene in ovulation induction. preliminary observations showed that tamoxifen does not cause a negative effect on the endometrium as compared with clomiphene, and may increase the chance to conceive in those patients who have a thin endometrium under clomiphene.


Eligibility criteria:
inclusion criteria: * primary or secondary infertility due to: * ovulatory dysfunction * mild male infertility * unexplained infertility * endometrium \< 6 mm at time of hcg during previous treatment with clomiphene citrate * age 18-35 exclusion criteria: * serious adverse effects under clomiphene citrate or known sensitivity to either tamoxifen or clomiphene citrate

Keywords: infertility ovulation dysfunction endometrium tamoxifen clomiphene citrate
validation of a hypertension education program

Conditions: Arterial Hypertension

Summary: the primary purpose of this study is to assess the effect of participating in the interactive hypertension education program of the german hypertension league (dhl©) "my blood pressure - ok!" on office systolic blood pressure.


Eligibility criteria:
inclusion criteria: * \> 21 years of age * primary arterial hypertension * office blood pressure between 140/90 mmhg and 160/100 mmhg exclusion criteria: * participation in another clinical study * unstable clinical condition * secondary arterial hypertension * dementia * major disability (modified rankin-scale \> 4) * severe chronic kidney disease (serum creatinine \> 2.0 mg/dl or estimated glomerular filtration rate \< 40 ml/min/1.73m2) * liver disease including history of hepatic encephalopathy, esophageal varices or portacaval shunt * history of gastrointestinal operation or disease with a potential influence on drug absorption * allergy or other contraindications against drugs given during the study * history of non-compliance
efficacy of sens 401 in subjects with severe or profound sudden sensorineural hearing loss

Conditions: Severe Sudden Sensorineural Hearing Loss

Summary: primary objective of the study is to assess the efficacy of sens-401 on hearing loss in comparison to placebo at the end of the 4-week treatment period

patients will receive the study drug (sens-401 or placebo) in the form of tablets by mouth, twice a day (3 tablets in the morning and 3 tablets in the evening), during the first 4 weeks after randomization. sens-401 is an investigational medicinal product. it belongs to a family of drugs known as "5 ht3 antagonist".

Eligibility criteria:
the main criteria for inclusion: * male or female aged at least 18 years old * patients with unilateral idiopathic sudden sensorineural hearing loss or unilateral/bilateral acute acoustic trauma leading to sudden sensorineural hearing loss. * patients with sudden hearing loss with onset within 96 hours prior to prior to first study drug intake. * patients under highly effective contraception the main criteria for exclusion: * bilateral idiopathic hearing loss * fluctuating hearing loss * history of asymmetric hearing (\>20 db difference between ears) to the best knowledge of the patient * severe hearing loss (\>90 db) associated with unilateral (ipsilateral) complete vestibular loss. * history of ménière's disease, autoimmune hearing loss, radiation-induced hearing loss, acoustic neuroma (schwannoma), otosclerosis, suspected perilymph fistula or membrane rupture, suspected retro-cochlear lesion, or barotrauma * previous ssnhl in the affected ear within the past 6 weeks * complete loss of peripheral vestibular function on the affected side * any drug-based therapy for inner ear hearing loss that is ongoing or was performed in the past 6 weeks (except oral corticosteroids) * any ongoing or planned concomitant medication for the treatment of tinnitus until 6 weeks after administration. * any therapy known as ototoxic (e.g. aminoglycosides, cisplatin, loop diuretics, quinine etc.) at the current time or in the past 6 months or planned in the coming 3 months. * acute or chronic otitis media or otitis externa terminated less than 7 days * prior ear surgery of any kind (except ventilating tubes), or cochlear implants * known history of, or concomitant severe hepatic, gastrointestinal, cardiovascular, respiratory, neurological (except vertigo or tinnitus), hematological, renal, dermatological or psychiatric disease or substance abuse * neurological disorders including stroke, demyelinating disease, brain stem or cerebellar dysfunction within the last 3 months. * treatment with any investigational agent within 4 weeks or any past treatment with azasetron or with 5-ht3 antagonists, or any prior or planned treatment by antidepressant treatment containing serotoninergic agents. * patients with either a history of significant arrhythmia, or a history of conditions known to increase the proarrhythmic risk (e.g., congestive heart failure, long qt syndrome, hypokalemia etc...).
non-bridging fixator versus percutaneous pinning for distal radius fractures

Conditions: Radius Fractures

Summary: the treatment of extra-articular distal radius fractures is still controversial. in canada, most patients with unstable fractures are treated with pinning and cast. results are often associated with shortening and lack of function. the purpose of the study is to compare stabilization with a radio-radial fixator to the usual method, suggesting that the radio-radial fixator will provide more strength at 6 months follow-up.


Eligibility criteria:
inclusion criteria: * distal radius fracture frykman i or ii * unstable fracture according to lafontaine's criteria * fracture line more than 1cm form the joint line * closed fracture * age \> 18 years * surgery performed between 72 hours from the trauma * monotrauma * patient signed the informed consent exclusion criteria: * distal radius fracture frykman iii-vi (intra-articular fracture) * open fracture * polytraumatism * stable or non-displaced fracture

Keywords: radius fractures radio-radial fixator percutaneous pinning grip strength
evaluation of the pharmacokinetic drug-drug interactions between vx-993 and metformin in healthy adults

Conditions: Pain

Summary: the purpose of this study is to evaluate the pharmacokinetic drug-drug interactions, safety, and tolerability of co-administration of vx-993 and metformin in healthy participants.

this clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (that is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(a) of the public health service act and 42 cfr 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the public health service act or 42 cfr 11.24 and 11.44.).

Eligibility criteria:
key inclusion criteria: * body mass index (bmi) of 18.0 to 32.0 kilogram per square meter (kg/m\^2) * a total body weight of more than (\>) 50 kg * nonsmoker or ex-smoker for at least 3 months before the first study drug dose key exclusion criteria: * history of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug * any condition possibly affecting drug absorption, distribution, metabolism, or excretion other protocol defined inclusion/exclusion criteria may apply.
core muscle response to backward walking in patients with non specific low back pain

Conditions: Non-specific Low Back Pain

Summary: evaluation of core muscles endurance and strength following backward walking training programe

a randomized controlled trial will be conducted at the isokinetic laboratory, faculty of physical therapy, cairo university, to investigate the effect of backward walking training on core muscles strength and endurance, pain severity, and disability level in subjects with nslbp. sixty females clinically diagnosed with nonspecific low back pain with age range from 18-45 years will participate in the study. they will be randomly assigned into 3 groups according to the received intervention; backward walking group (bwg), core stability group (csg), and control group (cg). the isokinetic strength of trunk muscles, and hip extensors and abductors will be evaluated in a concentric mode of muscle contraction. mcgill's core endurance tests will be used to examine participants' core endurance. the visual analog scale will be used for measuring the pain intensity. the oswestry disability index will be used to assess pain related disability and quality of life in subjects with lbp.

Eligibility criteria:
inclusion criteria: * participants will be included if they have a history of lbp for more than 6 weeks before the study, or experienced at least 3 episodes of lbp each lasting more than one week, during the year before the study. exclusion criteria: * participants will be excluded if they have: 1. lbp as a result of a specific spinal condition (e.g. spondylolisthesis, or spinal stenosis). 2. previous abdominal or spinal surgery. 3. serious spinal conditions (e.g., vertebral fracture, tumor or infection). 4. severe musculoskeletal deformity (scoliosis or kyphosis). 5. inflammatory disorders (e.g. rheumatoid arthritis). 6. radicular symptoms consistent with a disc herniation, or cauda equina syndrome. 7. pain and dysfunction in the upper and lower extremity that would interfere with testing. 8. current pregnancy. 9. marked leg length discrepancy greater than 2 cm.

Keywords: nslbp
objective visual acuity measurement using suppression of the optokinetic nystagmus (okn).

Conditions: Visual Acuity

Summary: suppression of the optokinetic nystagmus when a target is perceived can be applied to assess visual acuity objectively. our aim is to establish prediction intervals for this optokinetic nystagmus suppression test (speedwheel test, sw) so that sw acuity may be used to estimate snellen acuity (fract- c and -e) in the clinic in adults and children unable to cooperate in other acuity testing.

in this prospective single center study subjects aged at least 4 years underwent testing of visual acuity with sw, landolt-c and tumbling-e symbols (freiburg acuity test: fract-c, fract-e). prediction intervals are to be established for sw compared to fract-c or -e and for fract- e compared to fract-c.

Eligibility criteria:
inclusion criteria: * able and willing to perform the test exclusion criteria: * under 4 years of age * unable or unwilling
effect of chest physiotherapy on clinical outcome of infants with bronchiolitis

Conditions: Bronchiolitis; Infant, Newborn, Diseases; Chest Physiotherapy; Educational Program

Summary: the goal of clinical trial study is to evaluate effect of chest physiotherapy educational on mother's knowledge, practice and clinical outcomes of infants aged less than 12 months diagnosed with bronchiolitis by physician the main questions aims to answer: * does chest physiotherapy improve clinical outcomes of infants with bronchiolitis? * does educational program improve mothers knowledge and practice regarding chest physiotherapy? researcher compare two groups one receive routine hospital care (control group) other receive chest physiotherapy applied by mothers in addition to routine hospital care and will be followed up for 3 days


Eligibility criteria:
inclusion criteria: * 1. mothers of infants diagnosed with bronchiolitis. 2. presence of crackle on auscultation. exclusion criteria: 1. children with contraindication of chest physiotherapy (ex. fracture, recent surgery) 2. children who intubated and admitted to intensive care unit (icu).
safety, acceptability and efficacy of a long-term intervention with a diabetes-specific low-carbohydrate, high-mono-unsaturated fatty acid containing oral nutritional supplement on glycaemic control in type 2 diabetic patients

Conditions: Diabetes

Summary: the purpose of the study is to determine the safety, acceptability and the efficacy of a 12-week intervention with a diabetes-specific oral nutritional supplement on glycaemic control in type 2 diabetic patients with or at risk of malnutrition


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes according to the who diagnostic criteria for more than 6 months: fasting plasma glucose (fpg) ≥ 126 mg/dl (7.0 mmol/l) or 2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an ogtt (oral glucose tolerance test); * hba1c between 6.5-8.5 % (confirmed in the previous 3 months), * capable of using oral nutritional supplementation, * on stable and controlled anti-diabetic regime for at least 1 months, * use of metformin and/or sulphonylureas as oral anti-diabetic medication, * in need of nutritional support because of ≥5% involuntary weight loss in the last 3 months, ≥10% involuntary weight loss in the last 6 months, inadequate nutritional intake causing failure to meet nutritional requirements or at risk of developing malnutrition exclusion criteria: * diabetes type 1, * participation in a clinical trial with an investigational product or regular use of disease-specific oral nutritional supplements within 4 weeks prior to study start * patients requiring a fibre free diet, * enteral tube feed or parenteral nutrition, * concomitant therapy with systemic glucocorticoids, insulins or anti-diabetic medication other than metformin and sulphonylureas, * known or suspected intolerance or allergy to any component of the investigational product(s), * any acute gastrointestinal disease within 2 weeks prior to study entry, * gastrectomy, gastroparesis or other gastric emptying abnormalities, * acute sever heart failure (nyha class 4), liver insufficiency / failure (male: alat \> 150 u/l; female: alat \> 120 u/l) or renal failure requiring dialysis, * cancer cachexia, * galactosaemia, fructosaemia, * suspicion of drug abuse, abuse of/addiction to alcohol, * pregnant or breast feeding women, or fertile women refusing to use contraceptives, * patients with untreated major psychiatric disorder, * known hiv positive (safety reasons), * patient unable to co-operate adequately

Keywords: oral nutritional supplement, diabetes mellitus type 2, glycaemic control oral nutritional supplement (food for special medical purposes)
individual factors of cbt underlying success

Conditions: Social Anxiety Disorder; Body Dysmorphic Disorder

Summary: the purpose of this study is to understand why some individuals respond fully to cognitive behavioral therapy and others do not, based on multiple sources of data such as neural, neurocognitive, clinical, and self-report data.

the investigators are conducting this research to evaluate the reliability and construct validity of measures of self-focused attention (sfa) across neural, neurocognitive, and self-report levels of analysis as well as examine whether early changes in the sfa biomarker are associated with cbt non-response. this will be looked at in a clinical population consisting of individuals with social anxiety disorder (sad) and body dysmorphic disorder (bdd) compared to healthy volunteers. this study employs an open clinical trial for cognitive behavioral therapy with pre-, mid- and post-treatment neuroimaging scans, clinical interviews, neurocognitive, behavioral, and self-report assessments. clinical participants will be invovled for 3.5 months and complete 12 cbt sessions and 4 fmri scans. control participants will not participate in cbt treatment and will complete 3 fmri scans across a 3.5 month period. about 160 people will take part in this research study, all at the university of washington (uw). this will include 110 clinical participants and 50 healthy control participants.

Eligibility criteria:
inclusion criteria: clinical sample (n=110): 1. men and women, age 18-45 2. treatment-seeking individuals who meet criteria for a primary dsm-5 diagnosis of primary social anxiety disorder (sad) or body dysmorphic disorder (bdd) based on the scid-5-rv 3. fluent in english and willing to provide informed consent. control sample (n=50): 1. men and women, age 18-45 2. no current or lifetime history of psychiatric disorders, as assessed using the scid-5-rv 3. meet criteria for low levels of anxiety (gad-7 score of \<8) and depression (phq-9 score \<10) 4. fluent in english and willing to provide informed consent exclusion criteria: all groups: 1. score \< 80 based on wrat5 word reading subtest 2. fmri contraindications (e.g., electronic medical devices such as pacemakers, implanted defibrillators, etc.; metal implants not approved for mri; pregnancy; claustrophobia) 2. active suicidal or homicidal ideation, or any features requiring a higher level of care 3. lifetime history of manic or hypomanic episode, psychotic symptoms, traumatic brain injury, neurological disorder, pervasive developmental disorder, or attention deficit-hyperactivity disorder; active alcohol or substance use disorder in the past 6 months 4. current use of psychotropic medications, except antidepressants taken at a stable dose for 3 months prior to study baseline 5. previous cbt non-responder or current cbt

Keywords: body dysmorphic disorder social anxiety disorder social phobia self focused attention fmri cbt cognitive behavior therapy bdd sad neuroimaging
straight versus coiled peritoneal dialysis catheter for peritoneal dialysis patients

Conditions: End-stage Renal Disease; Renal Failure

Summary: this study compares the result of straight versus coiled tenckhoff catheters for peritoneal dialysis patients. recent meta-analysis of the peritoneal dialysis catheter type was in favor of straight catheters. the effects of straight versus coiled peritoneal dialysis catheters, however, are unclear. the investigators design an adequately powered randomized controlled study to evaluate the two types of double-cuffed peritoneal dialysis catheters. the primary objective is to assess whether straight peritoneal dialysis catheters can reduce the risk of catheter dysfunction that requires intervention. the investigators estimate that they would need to enroll 132 incident peritoneal dialysis patients in each group for the study to have 80% power to detect a difference between 7% and 15% in the primary endpoint of catheter dysfunction requiring intervention.

the objective of the present study is to evaluate the a priori hypothesis that straight peritoneal dialysis catheters would improve the treatment outcomes of peritoneal dialysis. the early and late catheter complications, as well as catheter survival, will be compared between peritoneal dialysis patients who are randomized to straight and coiled tenckhoff catheters.

Eligibility criteria:
inclusion criteria: * requires dialysis catheter insertion for maintenance peritoneal dialysis * aged 18 or older * willingness to give written consent and comply with the study protocol exclusion criteria: * known contraindication to peritoneal dialysis * participation in another interventional study within last 30 days of randomization * history of a psychological illness or condition that would interfere with the patient's ability to understand the requirement of the study and/or comply with the dialysis procedures